PIOGLITAZONE HCL

Pioglitazone HCl is a thiazolidinedione that activates PPAR‑γ, improving insulin sensitivity and glucose uptake in type 2 diabetes. Benefits include reduced HbA1c and improved lipid profile. Side effects include weight gain, edema, risk of heart failure exacerbation, bone fractures, and possible bladder cancer risk with long‑term use.

SKU: 12c5251fc6ba Category: Tag:

Product Description


Mechanism of Action

PIOGLITAZONE HCL (ID 27120) demonstrates a broad, multi‑layer biochemical activity profile affecting enzyme‑driven catalytic pathways, receptor‑regulated signalling systems, mitochondrial bioenergetics, redox‑state equilibrium, ion‑channel behaviour, cytoskeletal integrity and transcription‑factor regulatory networks. Its structural features indicate potential interactions with catalytic residues, allosteric protein domains, membrane‑bound receptors and intracellular signalling intermediates, enabling influence over phosphorylation kinetics, Ca²⁺/cAMP/IP₃/DAG‑mediated second‑messenger systems, ATP turnover, ROS buffering and mitochondrial respiratory‑chain performance.

Depending on concentration and biological conditions, PIOGLITAZONE HCL may modulate metabolic flux distribution, alter mitochondrial membrane potential, influence chromatin accessibility, impact vesicular trafficking dynamics and reshape gene‑expression patterns relevant to survival, inflammation, apoptosis, autophagy, metabolic adaptation and redox‑stress response.

Benefits and Advantages

This compound is widely used across advanced biochemical, pharmacological and mechanistic research domains, including:

  • Receptor–ligand interaction studies and affinity‑mapping
  • Enzyme‑kinetic pathway deconstruction and catalytic‑domain profiling
  • Mitochondrial‑function analysis and ATP‑flux/oxidative‑stress modelling
  • Multi‑omics integration (transcriptomics, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal‑structure and membrane‑dynamics research
  • Autophagy, apoptosis, necroptosis and ferroptosis signalling investigations
  • SAR (structure–activity relationship) profiling and compound‑optimisation workflows
  • Pharmacodynamic modelling, threshold‑activation mapping and dose–response scaling

Side Effects and Risks

Laboratory‑observed or predicted risks include:

  • Oxidative imbalance and excessive ROS accumulation
  • Mitochondrial overload or respiratory‑chain suppression
  • Dysregulation of Na⁺/K⁺/Ca²⁺ ion‑channel homeostasis
  • Unintended receptor cross‑talk or inhibitory interference
  • Cytoskeletal destabilisation and membrane‑integrity disruption
  • Dose‑dependent cytotoxicity with apoptosis/autophagy activation
  • Transcriptional instability or epigenetic disturbance
  • Inflammatory signalling activation via NF‑κB, MAPK or JNK pathways

Use strictly within controlled laboratory environments under appropriate biosafety protocols.

Datasheet


Molecular Formula

C19H20N2O3S·HCl

Molecular Weight

392.9 g/mol

CAS Number

112529-15-4

Storage Condition

Storage: Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F).

Solubility

1.8 [ug/mL] (The mean of the results at pH 7.4)

Purity

Purity information is available upon request (COA).

Synonym

pioglitazone hydrochloride; 112529-15-4; Pioglitazone HCl; Piomed; JQT35NPK6C

IUPAC/Chemical Name

5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride

InChl Key

GHUUBYQTCDQWRA-UHFFFAOYSA-N

InChl Code

InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H

References

https://pubchem.ncbi.nlm.nih.gov/compound/60560;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download